Sulesomab

N/A

Report date: 2025/09/05 17:58:18

Base Information

Drug NameSulesomab

Drug Alias Name硫索单抗Immu/RAID-MN3ImmuRAID MN3 Tc 99m苏来索单抗sulesomabum +[9]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[7]

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsRadionuclide imaging enhancersAnti-CEACAM6

TargetsCarcinoembryonic antigen related cell adhesion molecule 5Carcinoembryonic antigen related cell adhesion molecule 6

Therapy Area/IndicationsOsteomyelitis

Global Approved IndicationsOsteomyelitis

Approved Indications in ChinaN/A

Original Approved Country/TerritoryEU

Original Approved Date1997/02/14

Country/TerritoryEU

CombinationsNo

Global Highest StatusWithdrawn

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Gmbh

Active IndicationsN/A

Inactive IndicationsOsteomyelitis

Other Information

ATC CodeV09HA04